Healthcare
Regen BioPharma, Inc.(RGBP)
Live Price
Offline$0.0002
+100.00% today
1Y Change
-99.82%
Window
Jun 23, 2025 โ Jun 9, 2026
- Market Cap
- โ
- Revenue Growth
- +0.0%
- EPS Growth
- +66.1%
- Dividend Yield
- 0.0%
Coverage: 243 bars ยท Jun 23, 2025 โ Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Regen BioPharma, Inc. (RGBP) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 99.8% across the available one-year price window (Jun 23, 2025 โ Jun 9, 2026). Baseline metrics include revenue growth of +0.0%, EPS growth of +66.1%, a dividend yield of 0.0%. What stands out right now is revenue +0.0%, EPS +66.1%, free cash flow +44.7% with operating margin -350.3% and ROIC 15.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Stock Foundry combines RGBP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.0% vs +7.6% peer median
Operating Margin
Below sector median
-350.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +0.0% and EPS at +66.1%, with operating margin around -350.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -27.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -20.0% | -20.0% | -60.0% |
2026 Jan 29, 2026 | โ | -7.9% | -43.5% | -82.9% |
2025 Nov 27, 2025 | โ | +0.5% | -17.8% | -13.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGBP
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RGBP Max Drawdown
-99.89%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RGBP and SPY.
Company Overview
Regen BioPharma, Inc.
Other OTC
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is in the early stages of development of its products, and therapies. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.
- Leadership
- David Raymond Koos
- IPO Date
- Oct 6, 2014
- Employees
- 1
- Street Address
- 4700 Spring Street
- Mailing
- La Mesa, CA, 91942
- Region
- La Mesa, CA, US
- Reporting Currency
- USD
- Investor Line
- 619 722 5505
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.0
- Price/Book
- โ
Growth
- Revenue
- +0.0%
- EPS
- +66.1%
- Free Cash Flow
- +44.7%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -350.3%
- Net Margin
- -730.0%
- ROE
- 28.3%
- ROIC
- 15.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.